Depomed (DEPO) : Traders are bullish on Depomed (DEPO) as it has outperformed the S&P 500 by a wide margin of 13.03% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.41%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.46% in the last 1 week, and is up 14.2% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 8.93% and the 50-Day Moving Average is 9.34%. Depomed (NASDAQ:DEPO): The stock was completely flat for the day, closing at $21.48 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $21.52, the stock touched an intraday high of $21.69 and a low of $21.18. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $21.48. The total trading volume on Friday was 739,139.
The company Insiders own 5.12% of Depomed shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -28.21% . During last six month period, the net percent change held by insiders has seen a change of -46.62%. Also, Equity Analysts at the JMP Securities maintains the rating on Depomed (NASDAQ:DEPO). The brokerage firm has issued a Market Outperform rating on the shares. The Analysts at the ratings agency lowers the price target from $28 per share to $22 per share. The rating by the firm was issued on August 4, 2016.
Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Companys products include Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Gralise is a once-daily product for the management of postherpetic neuralgia (PHN). CAMBIA is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks. Zipsor, a liquid filled capsule, is a NSAID for the treatment of mild to moderate acute pain. Lazanda nasal spray is used for the management of break through pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. It also has a portfolio of license agreements based on its Acuform gastroretentive drug delivery technology. The Companys product DM-1992 has completed a Phase II trial for Parkinsons disease.